查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1621585

疫苗佐劑市場：按產品、給藥途徑、疾病和應用 - 全球預測 2025-2030

Vaccine Adjuvants Market by Product (Adjuvant Emulsions, Combination Adjuvants, Mineral Adjuvants), Route of Administration (Intradermal, Intramuscular, Intranasal), Disease, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年疫苗佐劑市值為8.2565億美元，預計2024年將達到8.8418億美元，複合年成長率為7.88%，到2030年將達到14.042億美元。

疫苗佐劑是透過調節免疫反應來提高疫苗有效性的重要成分。對佐劑的需求在於其能夠增強對抗原的免疫反應，減少所需抗原的量，並提高疫苗的穩定性，特別是在開發針對愛滋病毒、瘧疾和癌症等挑戰性疾病的新疫苗方面已成為當務之急。特別是，它對於開發針對愛滋病毒、瘧疾和癌症等不治之症的新疫苗至關重要。這些疫苗主要用作感染疾病的預防性疫苗以及慢性病和癌症的治療性疫苗。典型的最終用途領域包括製藥公司、學術研究機構和生技公司。市場發展受到感染疾病和慢性病日益普及、對免疫計劃的日益關注、佐劑配方的進步以及政府對疫苗開發的支持政策的影響。最近的技術創新，例如新的輸送系統和下一代佐劑配方，提供了成長機會。為了利用這些優勢，相關人員應專注於擴大策略夥伴關係和研發投資，特別是在免疫需求未被滿足的新興市場。然而，他們面臨挑戰，例如疫苗核准的嚴格監管指南、免疫抗原性問題以及與佐劑相關的潛在副作用，這些可能會阻礙採用率。高研發和生產成本也是許多公司的限制因素。創新領域包括開發可誘導更廣泛免疫反應的佐劑、兒科佐劑和抗流行病佐劑，這可以提供顯著的市場優勢。該市場競爭激烈，強調以研究主導的成長策略。總體而言，確保安全性和有效性的輔助技術進步以及促進核准順利的監管策略對於獲得市場佔有率至關重要。透過與政府和非政府組織合作，繼續走在創新前沿的公司將最有能力在不斷發展的疫苗開發領域取得成功。

主要市場統計
基準年[2023] 8.2565億美元
預計年份 [2024] 88418萬美元
預測年份 [2030] 1,404.2 百萬美元
複合年成長率（%） 7.88%

市場動態：揭示快速發展的疫苗佐劑市場的關鍵市場洞察

供需的動態交互作用正在改變疫苗佐劑市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 感染疾病和通用感染疾病的增加
    • 需要提高疫苗的有效性
    • 畜牧業的發展和相關疾病的流行
  • 市場限制因素
    • 礦物佐劑與重組蛋白及次單位疫苗的不相容性
  • 市場機會
    • 增加組合佐劑的潛力
    • 加大疫苗研發力度
  • 市場挑戰
    • 資本密集且耗時的開發與核准流程

波特的五力戰略工具駕馭疫苗佐劑市場

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢、解決弱點並避免潛在的挑戰，以確保更強大的市場地位。

PESTLE分析：了解外部對疫苗佐劑市場的影響

外部宏觀環境因素對疫苗佐劑市場的表現動態起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解疫苗佐劑市場的競爭狀況

疫苗佐劑市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的見解，以應對日益激烈的競爭。

FPNV定位矩陣疫苗佐劑市場供應商績效評估

FPNV定位矩陣是評估疫苗佐劑市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議繪製疫苗佐劑市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，對疫苗佐劑市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開發：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、未開發地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 感染疾病和通用感染疾病的發生率增加
      • 需要提高疫苗的有效性
      • 畜牧業的擴張和相關疾病的傳播
    • 抑制因素
      • 礦物佐劑與重組蛋白及次單位疫苗的不相容性
    • 機會
      • 複合佐劑的潛力不斷成長
      • 擴大疫苗開發
    • 任務
      • 資本密集且耗時的開發與核准流程
  • 市場區隔分析
    • 疾病：使用疫苗佐劑來提高癌症疫苗的有效性激增
    • 產品：佐劑乳劑在免疫力較弱的人中越來越受歡迎。
    • 應用：增加人類疫苗中疫苗佐劑的使用
    • 給藥途徑：透過皮內給藥增加疫苗佐劑的使用
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章疫苗佐劑市場：依產品

  • 佐劑乳劑
  • 複方佐劑
  • 礦物佐劑
  • 顆粒佐劑

第7章疫苗佐劑市場：依給藥途徑分類

  • 皮內
  • 肌肉注射
  • 鼻內
  • 口服
  • 皮下的

第8章 疫苗佐劑市場：依疾病分類

  • 癌症
  • 感染疾病

第9章疫苗佐劑市場：依應用分類

  • 人類
  • 獸醫

第10章 美洲疫苗佐劑市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太疫苗佐劑市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東和非洲疫苗佐劑市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 普立茲克分子工程學院開始產學合作開發下一代疫苗
    • Croda Partners 疫苗佐劑
    • 牛津大學開發的 R21/Matrix M 瘧疾疫苗獲准在加納使用
  • 戰略分析和建議

公司名單

  • Agenus Inc.
  • Aphios Corporation
  • Bioveta, AS
  • Croda International PLC
  • CSL Limited
  • Dynavax Technologies Corporation
  • GlaxoSmithKline PLC
  • Hayashibara Co., Ltd. by NAGASE & CO., LTD.
  • InvivoGen
  • Merck KGaA
  • Novavax, Inc.
  • OZ Biosciences SAS
  • Pacific GeneTech Limited
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc.
Product Code: MRR-02026C4C8667

The Vaccine Adjuvants Market was valued at USD 825.65 million in 2023, expected to reach USD 884.18 million in 2024, and is projected to grow at a CAGR of 7.88%, to USD 1,404.20 million by 2030.

Vaccine adjuvants are critical components used to enhance the efficacy of vaccines by modulating the immune response. The necessity of adjuvants lies in their ability to enhance immune reactions to antigens, reduce the amount of antigen required, and improve vaccine stability, making them indispensable in developing new vaccines, especially for challenging diseases like HIV, malaria, and cancer. They are predominantly applied in prophylactic vaccines for infectious diseases and therapeutic vaccines targeting chronic diseases and cancers. Key end-use sectors include pharmaceutical companies, academic research institutions, and biotechnology firms. Market growth is influenced by the rising prevalence of infectious and chronic diseases, increasing focus on immunization programs, advancements in adjuvant formulations, and supportive government policies for vaccine development. Recent technological innovations, such as novel delivery systems and next-generation adjuvant formulations, present opportunities for growth. To capitalize on these, stakeholders should focus on strategic partnerships and increased R&D investments, especially in emerging markets with unmet immunization needs. However, the market faces challenges such as stringent regulatory guidelines for vaccine approval, immunogenicity concerns, and potential side effects associated with adjuvants, which can hinder adoption rates. The high cost of research and production can also pose a limitation for many firms. Areas ripe for innovation include the development of adjuvants that can induce broader immune responses, pediatric-specific adjuvants, and adjuvants for use in pandemic preparedness, which could offer significant market advantages. The market is highly competitive, with a strong emphasis on research-driven growth strategies. Overall, advancing adjuvant technologies that ensure safety and efficacy, along with regulatory strategies that facilitate smoother approvals, will be vital for capturing market share. Firms that stay ahead in innovation, forming alliances with both governmental and non-governmental organizations, will be best positioned for success in the evolving landscape of vaccine development.

KEY MARKET STATISTICS
Base Year [2023] USD 825.65 million
Estimated Year [2024] USD 884.18 million
Forecast Year [2030] USD 1,404.20 million
CAGR (%) 7.88%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Vaccine Adjuvants Market

The Vaccine Adjuvants Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing incidences of infectious and zoonotic diseases
    • Need to increase the effectiveness of vaccines
    • Growth in livestock operations and prevalence of associated diseases
  • Market Restraints
    • Incompatibility of mineral adjuvant with recombinant proteins and sub-unit vaccines
  • Market Opportunities
    • Rising potential of combination adjuvants
    • Increasing development of vaccines
  • Market Challenges
    • Capital-intensive and time-consuming development and approval process

Porter's Five Forces: A Strategic Tool for Navigating the Vaccine Adjuvants Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Vaccine Adjuvants Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Vaccine Adjuvants Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Vaccine Adjuvants Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Vaccine Adjuvants Market

A detailed market share analysis in the Vaccine Adjuvants Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Vaccine Adjuvants Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Vaccine Adjuvants Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Vaccine Adjuvants Market

A strategic analysis of the Vaccine Adjuvants Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Vaccine Adjuvants Market, highlighting leading vendors and their innovative profiles. These include Agenus Inc., Aphios Corporation, Bioveta, A.S., Croda International PLC, CSL Limited, Dynavax Technologies Corporation, GlaxoSmithKline PLC, Hayashibara Co., Ltd. by NAGASE & CO., LTD., InvivoGen, Merck KGaA, Novavax, Inc., OZ Biosciences SAS, Pacific GeneTech Limited, Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Vaccine Adjuvants Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Adjuvant Emulsions, Combination Adjuvants, Mineral Adjuvants, and Particulate Adjuvants.
  • Based on Route of Administration, market is studied across Intradermal, Intramuscular, Intranasal, Oral, and Subcutaneous.
  • Based on Disease, market is studied across Cancer and Infectious Diseases.
  • Based on Application, market is studied across Human and Veterinary.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidences of infectious and zoonotic diseases
      • 5.1.1.2. Need to increase the effectiveness of vaccines
      • 5.1.1.3. Growth in livestock operations and prevalence of associated diseases
    • 5.1.2. Restraints
      • 5.1.2.1. Incompatibility of mineral adjuvant with recombinant proteins and sub-unit vaccines
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising potential of combination adjuvants
      • 5.1.3.2. Increasing development of vaccines
    • 5.1.4. Challenges
      • 5.1.4.1. Capital-intensive and time-consuming development and approval process
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Diseases: Burgeoning use of vaccine adjuvants to increase the efficacy of cancer vaccines
    • 5.2.2. Product: Increasing preference for adjuvant emulsions for those with compromised immune systems
    • 5.2.3. Application: Increasing use of vaccine adjuvants for human vaccines
    • 5.2.4. Route of Administration: Proliferating use of vaccine adjuvants through intradermal administration
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Vaccine Adjuvants Market, by Product

  • 6.1. Introduction
  • 6.2. Adjuvant Emulsions
  • 6.3. Combination Adjuvants
  • 6.4. Mineral Adjuvants
  • 6.5. Particulate Adjuvants

7. Vaccine Adjuvants Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Intradermal
  • 7.3. Intramuscular
  • 7.4. Intranasal
  • 7.5. Oral
  • 7.6. Subcutaneous

8. Vaccine Adjuvants Market, by Disease

  • 8.1. Introduction
  • 8.2. Cancer
  • 8.3. Infectious Diseases

9. Vaccine Adjuvants Market, by Application

  • 9.1. Introduction
  • 9.2. Human
  • 9.3. Veterinary

10. Americas Vaccine Adjuvants Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Vaccine Adjuvants Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Vaccine Adjuvants Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Pritzker School of Molecular Engineering enters Academic-Industry partnership to create Next Generation vaccines
    • 13.3.2. Croda Partners on Vaccine Adjuvants
    • 13.3.3. R21/Matrix-M Malaria Vaccine Developed By University Of Oxford Receives Regulatory Clearance For Use In Ghana
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Agenus Inc.
  • 2. Aphios Corporation
  • 3. Bioveta, A.S.
  • 4. Croda International PLC
  • 5. CSL Limited
  • 6. Dynavax Technologies Corporation
  • 7. GlaxoSmithKline PLC
  • 8. Hayashibara Co., Ltd. by NAGASE & CO., LTD.
  • 9. InvivoGen
  • 10. Merck KGaA
  • 11. Novavax, Inc.
  • 12. OZ Biosciences SAS
  • 13. Pacific GeneTech Limited
  • 14. Takeda Pharmaceutical Company Limited
  • 15. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. VACCINE ADJUVANTS MARKET RESEARCH PROCESS
  • FIGURE 2. VACCINE ADJUVANTS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL VACCINE ADJUVANTS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. VACCINE ADJUVANTS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. VACCINE ADJUVANTS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. VACCINE ADJUVANTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL VACCINE ADJUVANTS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. VACCINE ADJUVANTS MARKET DYNAMICS
  • TABLE 7. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ADJUVANT EMULSIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY COMBINATION ADJUVANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY MINERAL ADJUVANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PARTICULATE ADJUVANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY HUMAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY VETERINARY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 192. VACCINE ADJUVANTS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 193. VACCINE ADJUVANTS MARKET, FPNV POSITIONING MATRIX, 2023